Skip to main content
. Author manuscript; available in PMC: 2013 Dec 25.
Published in final edited form as: J Am Coll Cardiol. 2012 Nov 21;60(25):2653–2661. doi: 10.1016/j.jacc.2012.08.1010

Table 6. MW test for HF: 6MW to predict outcomes, and studies comparing 6MW and CPX.

Prior Study Study Population Results
6MW test as a prognostic marker
Bittner, et al. (19) 833 patients

  • LVEF37±14%

  • NYHA class 1.8

  • 15% on beta-blockers

 <300 m quartile: Significantly
greater chance of death (10.23%
vs. 2.99%; p=0.01),
hospitalization (40.91% vs.
19.90%; p=0.002), and HF
hospitalization (22.16% vs.
1.99%; p<0.0001).
Bettencourt et al. (20) 139 patients

  • LVEF 33.5±13.2%

  • NYHA class 1.9;

  • 25.2% on beta-blockers

 <350 m independently predicted
all-cause mortality
Ingle et al (21) 1,592 HF patients

  • Mean LVEF 48%; range 35-56%

  • NYHA class I-IV [specific proportions not clarified]

  • 42.2% on beta-blockers

 6MWD independently predicted
mortality among patients with
>mild left ventricular systolic
dysfunction
6MW test for prognostication in comparison to CPX
Cahalin et al (22) 45 patients

  • LVEF 20±6%

  • NYHA class 3.3

  • Beta-blocker unreported

  • 6MWD correlated with peak VO2 (r=0.64, p<.001)

  • 6MWD <300 m predicted a combined endpoint of death and/or hospitalization for transplant (p=0.04)
Roul et al (23) 121 patients

  • LVEF 29±13

  • NYHA 2.4

  • Beta-blocker unreported

  • 6MWD correlated to peak VO2 for patients who walked ≤300 m (r=0.65)

  • Events significantly higher in those who walked ≤300 m
Zugck et al (24) 113 patients

  • LVEF19±7

  • NYHA 2.2

  • 17% using beta-blocker

  • 6MWD correlated strongly with peak VO2 (r=0.68)

  • 6MWD prognostic assess-ment similar to peak VO2
Lucas et al (25) 307 patients

  • LVEF 23% average

  • Patients under evaluation for transplant

  • Shorter 6MWD correlated to lower Peak VO2

  • Peak VO2 predicted survival, but 6MWD did not
Opasich et al (26) 315 HF patients

  • Mean LVEF 26±8%

  • NYHA class 2.4

  • Beta-blockers not reported

  • 6MWD is a univariate prognostic marker

  • When entered into a model with NYHA and peak VO2, prognostic value of 6MWD diminished
Guazzi et al (2) 253 HF patients

  • LVEF 36.3±11.4%

  • NYHA class 2.2±0.78

  • 58.5% on beta-blockers

  • 6MWD correlated with peak VO2 and VE/VCO2 slope, but did not predict mortality
Rostagno, et al (27) 214 patients

  • LVEF 42%

  • NYHA class 2.1

  • 25% on beta-blockers

  • Survival significantly lower among those who walked <300 meters

  • Peak VO2 provided no prognostic value